Introduction
Retroviral vectors are effective tools for the genetic modification of eukaryotic cells including hematopoietic stem cells and T lymphocytes. One growing field of application is the retrovirus-mediated transfer of T-cell receptor (TCR) or chimeric single-chain receptor genes to redirect the specificity of healthy donor's or patient's T cells against virus-infected and tumor cells, which can then be therapeutically used for adoptive T-cell transfer. [1] [2] [3] Retrovirus vector particles can be generated by (i) transient triple transfection of the corresponding constructs (packaging, envelope and transfer vector) into suitable cell lines, (ii) transient transfection of the transfer vector into established packaging cell lines and (iii) stable transfection of the transfer vector into established packaging cell lines and subsequent selection and characterization of high-titer virus-producing cell clones. [4] [5] [6] [7] [8] Although the first two methods are less time consuming and high vector titers can be achieved, they require large amounts of plasmid DNA and are problematic in terms of upscaling. Moreover, vector particles produced by transient transfection may not be useful for application in clinical gene therapy trials because of lacking reproducibility. The generation of stable packaging cell clones ensures a continuous source of vector particles and their extensive quality control, but is laborious.
One prerequisite for vector particle production is the selection of packaging cells that continuously produce high vector titers. In general, this problem is solved by the introduction of a selectable marker gene together with the gene of interest into the retroviral vector. Drug resistance genes (e.g. neomycin, puromycin) allow positive selection of cells, but require days to weeks of growth in selective medium and the subsequent isolation and characterization of a large number of marker generesistant cell clones. Alternatively, the application of marker genes like green fluorescence protein (GFP) allows the simple detection of cells and offers the possibility for immediate enrichment by fluorescenceactivated cell sorter (FACS). However, most marker gene products are immunogenic and their usage is not advisable in many gene therapy applications including, for example, adoptive transfer of gene-modified T cells. 9 Furthermore, marker gene expression in retroviral vectors is often regulated by an internal promoter and interference with the commonly used long terminal repeat (LTR) promoter that regulates the expression of the therapeutic gene cannot be excluded. 10 However, without the application of selection marker, it is laborious and difficult to identify high-titer producer clones. Therefore, it would be convenient if the selection of high-titer virus-producing cells is based on a functional principle delivered by the transgene encoded by the vector. Here, we report on the generation of stable suspension packing cell lines based on the human lymphoblastoid T-cell line Db-Jurkat for the simplified generation of TCRretrovirus particles. Db-Jurkat cells lack CD3 surface protein expression owing to the deficiency of endogenous TCRb-chains. The transfer of a TCR-encoding retroviral vector complements this deficiency through the expression of the transgenic TCRb-chain. Cells expressing the CD3 complex on the surface can be detected with an anti-CD3 mAb, enriched by FACS, and represent the high-titer vector particle-producing cell fraction.
Results

Db-Jurkat cells expressed Gag proteins and exhibited reverse transcriptase (RT) activity
Db-Jurkat cells, which are not infected with HTLV-I or HTLV-II as determined by polymerase chain reaction (PCR) using virus-specific pol-and env-primers (data not shown), were electroporated with a plasmid containing the gag-pol gene of Murine leukemia virus (Mo-MLV). After selection of blasticidin S-resistant cells and cloning by limited dilution, 28 clones (cloning efficiency of 4.9%) were obtained and designated as Db-Jurkat/GP. Cell proteins of individual clones were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. A polyclonal goat anti-MLV p30 Ab was utilized to determine the expression level of the p30 capsid protein. Figure 1a shows the bulk culture and two clones (8 and 10) of Db-Jurkat/GP cells expressing high amounts of p30. No p30 protein expression was detected in parental Db-Jurkat cells, whereas the two established packaging cell lines 293-GALV and 293-10A1 expressed capsid protein. In addition to p30 expression, Gag precursor proteins with different molecular weights (Pr75 gag , Pr65 gag ) were also detected in all packaging cell lines, but not in Db-Jurkat cells. Although the different lanes were loaded with equal amounts of protein (each 50 mg) as proven by Ponceau-S staining of the nitrocellulose membrane (data not shown), Db-Jurkat/GP cells appeared to express higher amounts of Gag proteins in comparison with 293-GALV and 293-10A1 packaging cells (Figure 1a ).
To analyze whether or not functional proteins were synthesized from the pol gene, RT activity was determined in supernatants and pellets of gag-pol genetransferred Db-Jurkat/GP bulk culture and clones 8 and 10. Whereas the supernatants of Db-Jurkat/GP bulk culture and clones 8 and 10 yielded comparable levels of RT activity, the highest RT activity was found in the cell pellet of the Db-Jurkat/GP clone 10 ( Figure 1b) . From these data, we concluded that Db-Jurkat/GP cells express functional gag-pol gene-encoded proteins. We selected Db-Jurkat/GP clone 10 for the further construction of the packaging cell lines.
GALV and MLV-10A1 env gene-encoded proteins are efficiently expressed in Db-Jurkat/GP cells ALF plasmids expressing the GALV or the MLV-10A1 envelope proteins and the selectable marker phleomycin were utilized to generate GALV and MLV-10A1 pseudotype-producing cell lines. Electroporation of the ALF plasmids into Db-Jurkat/GP clone 10, phleomycin selection and subsequent cloning by limited dilution yielded 29 clones (cloning efficiency of 6.6%) of Db-Jurkat/ GP+GALV cells. These cells were tested for GALV env gene-specific RNA expression by reverse transcription (RT)-PCR because of lack of an Ab directed against GALV SU. Figure 2a shows the 910 bp SU PCR product obtained from the Db-Jurkat/GP+GALV bulk culture and cell clone 29, which yielded the most prominent band of all clones. As control, a PCR with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers was performed. The bands of the GALV SU-specific PCR were normalized by the intensity of GAPDHspecific bands of the same clone using Lumi-Imager F1. The ratios of GALV SU/GAPDH ranged from 0.5 to 1.6 for all clones including 1.6 for clone 29 (data not shown). 
Db-Jurkat packaging cells produced empty retrovirus particles
To analyze whether the packaging cell lines Db-Jurkat/ GP+GALV and Db-Jurkat/GP+10A1 produce empty retrovirus particles, supernatants of 5 Â 10 7 cells were harvested after 24 h and concentrated by ultracentrifugation. The pellets were lysed and Western blot analysis was performed using the p30 Ab. Prominent bands of p30 were visible in the supernatants of Db-Jurkat-based packaging cell lines and 293-GALV and 293-10A1 packaging cells used as control ( Figure 3 ). Additionally, Gag precursor proteins were detected in different amounts in all packaging cells. The supernatants of DbJurkat/GP+10A1 and 293-10A1 cells were also analyzed for Env protein expression by Western blot analysis with an anti-MLV gp71 mAb. This analysis revealed a considerably higher gp71 expression in 293-10A1 cell supernatant than in Db-Jurkat/GP+10A1 cell supernatant (data not shown).
Db-Jurkat packaging cells produced infectious retrovirus particles
Next, we analyzed the ability of Db-Jurkat/GP+GALV and Db-Jurkat/GP+10A1 packaging cells to produce infectious vector particles. Therefore, the packaging cells were transduced, with the GFP-retrovirus vector LEGSN and G418-resistant cells were used to produce vector particles. D17 cells were transduced, and after 48 h, GFP expression was measured by flow cytometry and the virus titer was calculated. The GFP-retrovirus produced from Db-Jurkat/GP+GALV packaging cells transduced 69711% of D17 cells, which corresponded to a titer of 3.971.1 Â 10 5 infectious particles (IP)/ml ( Figure 4 ). The supernatant of Db-Jurkat/GP+10A1 cells contained less GFP-retrovirus particles, nonetheless 31715% of D17 cells were transduced, which corresponded to a titer of 1.670.1 Â 10 5 IP/ml. This result confirmed the ability of both suspension packaging cell lines to produce infectious retrovirus vector particles. Similar transduction efficiencies were achieved when GFP-retroviruses produced from both packaging cell lines were utilized to transduce the T-cell line HuT78. The vector particles produced by Db-Jurkat/GP+GALV cells transduced 5175.4% of HuT78 cells (titer 4 Â 10 5 IP/ml), whereas Db-Jurkat/GP+10A1-produced vector particles were able to transduce 3578.0% (titer 2.8 Â 10 5 IP/ml) ( Figure 4 ).
Db-Jurkat packaging cells stably produced GFP-retrovirus vector particles
Then, we analyzed whether suspension packaging cells provide suitable properties for the production of retro- T-cell line-based packaging cells S Reu et al virus vector particles over an extended period of time.
To do so, the GFP-retrovirus-producing suspension cell lines Db-Jurkat/GP+GALV and Db-Jurkat/GP+10A1 and the adherently growing packaging cell lines 293-GALV and 293-10A1 were kept in culture for 4 weeks and vector particle-containing supernatant was analyzed in weekly intervals on D17 cells. Although the virus titer of the four packaging cell lines differed as indicated by the different percentage of GFP-transduced D17 cells, three of them showed a stable vector particle production over time (Figure 5a ). Only the packaging cell lines Db-Jurkat/ GP+GALV revealed a decrease in vector particle production within the first week, but produced similar amounts of vector particles within the remaining period of time.
Retrovirus vector particles produced by Db-Jurkat packaging cells are of similar stability as those from adherent packaging cell lines
We compared the stability of GALV-and MLV-10A1-pseudotyped GFP-retrovirus particles produced by Db-Jurkat-based packaging cells to those produced in adherent packaging cell lines 293-GALV and 293-10A1. Vector particle-containing supernatants were incubated from 3 to 30 h at 371C and used to transduce D17 cells. The transduction efficiency of supernatant that was not incubated at 371C was set at 100% and the transduction efficiencies obtained at other incubation times were related to it. As illustrated in Figure 5b , vector particles produced in Db-Jurkat/GP+10A1 and Db-Jurkat/ GP+GALV have half-lives of 6.5 and 9 h, respectively, whereas the half-lives of GFP-retroviruses produced in the adherent packaging cells 293-10A1 and 293-GALV were slightly higher (each 11 h).
No replication-competent retrovirus (RCR) was produced in Db-Jurkat packaging cells
To analyze if any recombination occurred between retroviral constructs and endogenous retroviral sequences, D17 cells were transduced with LEGSN vector particles produced by Db-Jurkat/GP+GALV and DbJurkat/GP+10A1 cells and kept in culture for 1 month under G418 selection. After 2 and 4 weeks, supernatants of transduced D17 cells were used to test for the presence of RCR using D17 cells. After 48 h, these cells were analyzed by flow cytometry for GFP expression. No GFPpositive cells were found in 50 000 cells (data not shown).
In addition, PCRs performed with p30 and GALV or MLV-10A1 env-specific primers were carried out with genomic DNA of transduced D17 cells and did not detect virus-specific sequences (data not shown). 
Discussion
We report the construction of new packaging cell lines for the simplified generation of TCR-retrovirus vector particles. We took advantage of the situation that the human lymphoblastoid T-cell line Db-Jurkat is deficient for the expression of the endogenous TCRb-chain. This deficiency leads to a failure of the presentation of the CD3 complex on the cell surface, although all CD3 components are synthesized and present in the cytoplasm. The transfer of a retrovirus vector encoding a therapeutic TCR into Db-Jurkat packaging cells complemented the missing endogenous TCRb-chain by the transgenic TCRb-chain and allowed the expression of TCR/CD3 complexes at the cell surface. These complexes were utilized to enrich vector producer cells by FACS or MACS techniques. In this regard, it is of particular importance that there is a direct correlation of the TCRb-chain and CD3 expression on the cell surface because (i) the transgene product itself allows a direct selection of high-titer producer cells, (ii) in situations where antibodies directed against the TCRb-chain are not available, the enrichment of CD3-positive cells can be used instead and (iii) the utilization of a cell surface marker (TCRb-chain, CD3) for cell enrichment avoids negative effects of selectable marker genes when introduced into a retrovirus vector and transferred into target cells such as T cells 9 or hematopoietic stem cells. Previously, it was demonstrated that suspension cells can be used to construct retrovirus packaging cell lines. Chan et al.
11 used a human lymphoblastoid B-cell line (WIL-2), whereas Pizzato et al. 12 used a lymphoblastoid B-cell line (Namalwa) and a T-cell line (CEM) to generate T-cell line-based packaging cells S Reu et al packaging cell lines. In these situations, vector particles were pseudotyped with the ecotropic or amphotropic MLV envelope. We have also constructed CEM-based packaging cell lines that produce MLV-10A1 and GALV vector pseudotypes (our unpublished data). However, CEM packaging cells harbor a complete endogenous TCR and express the CD3 complex on the cell surface. Thus, complementation of the CD3 expression by the transgenic TCR is not necessary, and therefore those cells cannot be utilized for the identification and enrichment of vector particle-producing cells by labeling with Ab directed against CD3.
We selected GALV and MLV-10A1 env genes for pseudotyping of vector particles. Previously, it was demonstrated that the GALV pseudotype uses the sodium-dependent phosphate transporter Pit1 and the MLV-10A1 pseudotype utilizes Pit1 and the related transporter Pit2 for entry into primary human T cells. [13] [14] [15] [16] Although Pit1 and Pit2 are expressed at different levels on the cell surface; they enable an efficient gene transfer into human T cells when GALV-or MLV-10A1-pseudotyped retrovirus vectors were employed. Thus, both envelopes are suitable for the genetic engineering of primary human T cells including the transfer of TCR genes that endow the specificity of T cells towards virusspecific or tumor-associated antigens.
We showed that Db-Jurkat cells synthesized gag-pol and MLV-10A1 and GALV env gene-encoded proteins and that these proteins are functional. The transduction with a GFP-encoding vector was used to prove proper function of transfected Db-Jurkat packaging cell lines. We showed that both packaging cell lines produce infectious GFP-retrovirus particles that transduced cells of canine (D17) and human (HuT78) origin and did not produce RCR.
When GFP-retrovirus production of Db-Jurkat-based packaging cell lines was analyzed for an extended period of time, there was no (Db-Jurkat/GP+10A1) or small (DbJurkat/GP+GALV) decrease in vector titer within 4 weeks. This indicated that the production of vector particles was stable. Thus, long-term cultivation of the suspension packaging cells should be less tedious in comparison with adherently growing packaging cells that need continuous trypsinization and reseeding.
Retrovirus vector particles are unstable and characterized by a rather short half-life. GFP-retroviruses produced in Db-Jurkat packaging cell lines revealed half-lives of 6.5 h for the MLV-10A1 pseudotype and 9 h for the GALV pseudotype, whereas half-lives of the same pseudotypes generated in 293 packaging cells were higher (GALV and MLV-10A1 pseudotypes each 11 h) at 371C. Pizzato et al. 12 and our earlier studies reported a half-life of the amphotropic MLV pseudotype produced in CEM and PA317 packaging cells, respectively, of approximately 4 h, whereas the same pseudotype produced in FLYA13 and CCRIP packaging cells showed a slightly higher stability. 17, 15 GALV and MLV-10A1 pseudotypes produced in the NIH3T3-derived packaging cell lines PG13 and PT67 have half-lives of 13 h and 14 h, respectively. 15 TCR-retrovirus produced in Db-Jurkat/GP+GALV packaging cells efficiently transduced human T-cell lines, whereas the transduction of primary human T cells was lower. This is most probably owing to the vector titer, which is high enough to transduce T-cell lines, but too low to achieve similar efficiencies in primary T cells. However, suspension cell-based packaging cells are qualified for the implementation of different tissue culture conditions to finally yield higher vector particle titers. Suspension cells can be grown to high densities in various tissue culture vials (e.g. spinner cultures, continuous flow-through systems). 18 Furthermore, time of vector particles harvest, temperature of cell growth as an important parameter of vector particle stability 19 and composition of tissue culture medium can be optimized to increase the vector titer.
In conclusion, we constructed T-cell line-based packaging cells and showed proof-of-principle that a cell surface protein (TCR) and its conjunction with a cell surface protein complex (CD3) can be utilized for the simple generation of high-titer vector-producing cells.
Materials and methods
Plasmids
The plasmid vector CeB encodes the Mo-MLV gag-pol gene and the selectable marker gene blasticidin S. 20 The plasmid vector pALF contains the GALV env gene or the MLV-10A1 env gene and the resistance gene phleomycin. 20, 21 The retroviral vector pLEGSN encodes the enhanced GFP gene and the neomycin resistance gene. The retroviral vector MP71-tcr26 encodes a human TCR (Va20-Ja22 [TRAV4*01-TRAJ22*01] and Vb22-Jb2.7 [TRBV2*03-TRBJ2-7*01]) isolated from a tumor-infiltrating T-cell clone (TIL-26) of a renal cell carcinoma patient.
22-24
Cells
Human T-cell lines Db-Jurkat (TIP153, American Type Culture Collection (ATCC), Manassas, VA, USA), HuT78 (TIP161, ATCC) and human peripheral blood lymphocytes (PBLs) were grown in Rosewell Park Memorial Institute 1640 GlutaMAX I medium supplemented with 10% heat-inactivated fetal calf serum (FCS, PAN Biotech GmbH, Aidenbach, Germany), 10 mM HEPES and 100 U/ml penicillin-streptomycin. PBLs were cultured with interleukin-2 (IL-2) (400 U/ml, Chiron, Munich, Germany). D17 canine osteosarcoma cells (CCL183, ATCC) were propagated in modified Eagle's medium alpha with 10% FCS. 293-GALV, 293-10A1 and FLYRD18 packaging cells 20, 25 were grown in Dulbecco's modified Eagle's medium with 10% FCS (Grainer, Frickenhausen, Germany). All cells were maintained at 371C and 5% CO 2 . All tissue culture media and additives were purchased from GIBCO (Karlsruhe, Germany) if not mentioned differently.
Transfection of packaging constructs and selection of cell clones
Transfer of pCeB and pALF plasmids into Db-Jurkat cells was performed as described. 12 Briefly, 1 ml (1 Â 10 7 cells) of a pre-cooled Db-Jurkat cell suspension was mixed with 10 mg of the pCeB plasmid DNA and transferred into a pre-cooled 0.4-cm cuvette. Electroporation was performed using a Gene Pulser II electroporater (Bio-Rad Laboratories GmbH, Munich, Germany) at a voltage of 250 mV and a capacitance of 960 mF. After electroporation, cells were resuspended in 9 ml of pre-warmed medium. After 24 h, cells were transferred into fresh /ml and selected with 6 mg/ml blasticidin S (Sigma-Aldrich Chemie, Munich, Germany). The bulk culture of blasticidin S-resistant Db-Jurkat cells was cloned by limited dilution at a concentration of 0.3 cells per well with 100 ml medium in a U-bottom 96-well plate (Costar, Corning, NY, USA). Db-Jurkat/gag-pol clones, designated as Db-Jurkat/GP, were expanded into individual cell lines. According to the same procedure, the pALF plasmid encoding the GALV env or the MLV-10A1 env gene was transferred into Db-Jurkat/GP cells. After selection with 50 mg/ml phleomycin (InvivoGen, San Diego, CA, USA), resistant cells were cloned by limited dilution and expanded into individual cell lines named as Db-Jurkat/GP+GALV or Db-Jurkat/GP+10A1, respectively.
Transfer of GFP and TCR retroviral vectors into Db-Jurkat/GP+GALV and Db-Jurkat/GP+10A1 packaging cell lines Transduction of packaging cells was performed as described. 15 Briefly, cells (2 Â 10 5 /well/ml) were seeded in non-tissue culture 24-well plates (Falcon, BD Biosciences Discovery Labware, Franklin Lakes, NJ, USA) coated with RetroNectin (8 mg/ml; TaKaRa Bio, Otsu, Japan). Transduction was performed with 1 ml virus supernatant in the presence of protamine sulfate (4 mg/ml; Sigma-Aldrich Chemie) and plates were subjected to spin oculation (1000 g, 90 min, 321C). Db-Jurkat/GP+GALV or Db-Jurkat/GP+10A1 cells were transduced with the LEGSN retrovirus pseudotyped with RD114 or GALV envelopes, respectively, and MP71-tcr26 retrovirus pseudotyped with MLV-10A1 or GALV envelopes, respectively.
FACS enrichment to generate high-titer TCR-retrovirus producer Db-Jurkat/GP+GALV and Db-Jurkat/ GP+10A1 packaging cells MP71-tcr26-transduced Db-Jurkat/GP+GALV and DbJurkat/GP+10A1 cells were expanded and approximately 3 Â 10 7 cells were stained with a phycoerythrin (PE)-conjugated CD3 mAb and sorted for CD3-high expressing cells. FACS sorting was performed at a cell density of 5-8 Â 10 6 /ml in phosphate-buffered saline (PBS) and 10% FCS and 200 U/ml penicillin-streptomycin using a FACS Vantage (Becton Dickinson Biosciences Immunocytometry Systems, San Jose, CA, USA). Enriched cells were grown at a density of 1 Â 10 6 /ml in medium with 200 U/ml of penicillin-streptomycin.
Production of vector particles and determination of vector titer
Vector particle production from suspension packaging cells was performed in T25 tissue culture flasks (Costar) at densities of 8 Â 10 6 cells/ml for 24 h at 321C and 8% CO 2 . Adherent packaging cells were grown to confluence in T25 (1 Â 10 6 ) or T75 (5 Â 10 6 ) tissue culture flasks (Costar). Then, the medium was exchanged and after 24 h virus supernatant was harvested. Cells and debris were removed from supernatants by low-speed centrifugation (400 g, 5 min, 41C) and by filtration through a 0.45-mm pore size filter. Vector production during longterm culture of packaging cells was carried out as follows: once per week, 8 Â 10 6 /ml of suspension packaging cells were seeded in T25 tissue culture flasks and grown at 321C. After 24 h, supernatant was harvested. Adherent packaging cells (1 Â 10 6 ) were seeded in 5 ml medium and cultured at 371C. After 24 h, medium was changed and after additional 24 h supernatant was harvested. Virus supernatants were filtered through a 0.45-mm pore size filter and stored at À801C. After virus harvest, cells were kept in culture until the next virus production cycle.
The GFP vector titer was determined on D17 cells, which were seeded at a density of 4 Â 10 4 cells per well, and per milliliter in a 24-well plate 24 h before. For transduction, the medium was exchanged with 1:2 diluted vector containing supernatant in a volume of 2 ml in the presence of polybrene (4 mg/ml; SigmaAldrich Chemie). After 24 h, the supernatant was replaced with fresh medium and after another 24 h the percentage of transduced D17 cells was determined using a flow cytometer FACSCalibur (Becton Dickinson) and CellQuest Pro software. The vector titer was calculated and indicated as IP/ml.
Transduction of cell lines and peripheral blood lymphocytes
After informed consent, PBLs were isolated from healthy donors by centrifugation on a Ficoll-Hypaque gradient (Seromed-Biochrom, Berlin, Germany) and stimulated for 72 h with 400 U/ml of IL-2 and immobilized anti-CD3 mAb (5 mg/ml) and anti-CD28 mAb (1 mg/ml; both BD Biosciences PharMingen, San Diego, CA, USA). PBLs (2 Â 10 5 /well/ml in the presence of 400 U/ml IL-2) and HuT78 T cells (2 Â 10 5 /well/ml) were transduced in RetroNectin-coated 24-well plates, as described above. Three days after transduction, cells were labeled with PE-conjugated vb22 mAbs.
Helper virus assay
D17 cells were transduced with GFP-retrovirus produced from Db-Jurkat/GP+GALV and Db-Jurkat/GP+10A1 packaging cells. GFP-positive D17 cells were enriched by selection with G418 (0.8 mg/ml) and cultured for 4 weeks. After 2 and 4 weeks, cell pellets were used for DNA isolation (Qiagen, Hilden, Germany) and genomic PCR. Supernatant was utilized to infect fresh D17 cells, and 2 days later cells were analyzed for GFP expression by flow cytometry.
Virus stability assay
GFP-retroviruses produced in Db-Jurkat/GP+GALV, DbJurkat/GP+10A1, 293-GALV and 293-10A1 packaging cells were harvested, filtered through a 0.45-mm pore size filter, and incubated at 371C for various periods from 3 to 30 h. Virus titers were determined by transduction of D17 cells with undiluted supernatant. Virus titer at t ¼ 0 (no incubation at 371C) was set at 100% and virus stability for each of the different incubation times was calculated.
Reverse transcriptase activity detection RT activity was determined in cell pellets and cell supernatants (Cavidi Tech; Uppsala, Sweden). Pellets of 1 Â 10 6 cells were washed with PBS, resuspended and diluted 1:100 in dilution buffer. Supernatants of Db-Jurkat cells, Db-Jurkat/GP+GALV and Db-Jurkat/ GP+10A1 (each 5 Â 10 6 /ml), were produced for 30 h at T-cell line-based packaging cells S Reu et al 321C and used in a dilution of 1:100 for the analysis of RT activity.
RT-PCR
Total RNA was isolated from 1 Â 10 7 cells using TRIzol reagent (Life Technologies, Rockville, MD, USA). RNA concentration was determined spectrophotometrically. A mixture of random hexanucleotides (Invitrogen, Karlsruhe, Germany) was used to prime cDNA synthesis in an in vitro reverse transcription reaction using SuperScript II reverse transcriptase (Invitrogen). Then, a 910-bp GALV SU product was amplified with the forward primer 5 0 -AAT AAG AAC CCC CAC CAG-3 0 and the reverse primer 5 0 -CCT GGG TTG GTA GCA TT-3 0 . As control for cDNA amounts, an RT-PCR was performed with GAPDH primers (forward 5 0 -ACC ACA GTC CAT GCC ATC AC-3 0 , reverse 5 0 -TCC ACC ACC CTG TTG CTG TA-3 0 ) generating a 451-bp product. RT-PCRs were carried out in a T-Personal thermocycler (Biometra, Gö ttingen, Germany) under the following conditions: single incubation at 941C for 5 min, 40 cycles (GALV SU) and 35 cycles (GAPDH) of 941C for 1 min, 60.51C for 1 min (551C for GAPDH), 721C for 1 min and a single extension at 721 for 10 min. A no-RT control was included as negative control. PCR products were analyzed on a 1% agarose gel.
Western blot analysis
Cells (1 Â 10 7 ) were washed twice with cold PBS and Western blot analysis was performed as described. 26 
